Benitec appoints new CEO
This article was originally published in Scrip
Dr Peter French has been appointed CEO of the Australian venture Benitec, effective immediately. He was formerly the chief scientific officer of the Melbourne-based RNAi technology company and succeeds Sue MacLeman. Benitec has a number of active therapeutic research programmes based on gene silencing approaches, including in hepatitis B, HIV/AIDS and lung cancer.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.